Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.

Name: Αlpha¹ Rigor Record — Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.
Item: Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.
Rating: 96
Author: Αlpha¹

Al-Samkari H, Kasthuri RS, Iyer VN, Pishko AM, Decker JE, Weiss CR, Whitehead KJ, Conrad MB, Zumberg MS, Zhou JY, Parambil J, Marsh D, Clancy M, Bradley L, Wisniewski L, Carper BA, Thomas SM, McCrae KR

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 3 high issues for “Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 15 reported means were read, and their group size is not stated where the values are printed. These checks need the count the mean was averaged over, so none was performed.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized, double-blind, placebo-controlled phase 2/3 trial with rigorous design, clear reporting of demographics, ethics, and statistical methods. The main weakness is the lack of a concrete data availability statement for individual patient data, and there are minor copyediting issues.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence to reconcile. The statistics verification component recomputed only 3 tests (all consistent); other statistics were not machine-verified. The citation check found no retracted or non-existent references.

5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior studies on HHT pathophysiology and antiangiogenic agents, including a 31-patient thalidomide study, and acknowledges limitations of prior work (e.g., non-randomized, underpowered). The rationale for pomalidomide is clearly linked to its favorable toxicity profile. Limitations of prior research are addressed by the randomized, placebo-controlled design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for testing pomalidomide.

Evidence

direct quote[Introduction, paragraph 3]

“Thalidomide, an immunomodulatory imide drug (IMiD), is the only antiangiogenic agent with positive prospective efficacy in HHT, demonstrated in a 31-patient study.”